Alpha 2.0
Login Register
» Authors » Leandro C Cerchietti

Leandro C Cerchietti

Explore the profile of Leandro C Cerchietti including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 442
Followers 0
Related Specialties
General Medicine
Oncology
Molecular Biology
Top 10 Co-Authors
Ari Melnick
Shao Ning Yang
Rita Shaknovich
Katerina Hatzi
Gabriela Chiosis
Karen L Bunting
Jose M Polo
Kapil N Bhalla
Ana I Robles
Lyuba Varticovski
Published In
Nat Med
Cancer Res
Cancer Cell
Blood
J Pain Symptom Manage
Affiliations
Soon will be listed here.
Recent Articles
1.
Author Correction: A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas
Cerchietti L, Lopes E, Yang S, Hatzi K, Bunting K, Tsikitas L, et al.
Nat Med . 2024 Apr; 30(5):1503. PMID: 38570701
No abstract available.
2.
BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy
Cerchietti L, Hatzi K, Caldas-Lopes E, Yang S, Figueroa M, Morin R, et al.
J Clin Invest . 2010 Nov; 120(12):4569-82. PMID: 21041953
B cell lymphoma 6 (BCL6), which encodes a transcriptional repressor, is a critical oncogene in diffuse large B cell lymphomas (DLBCLs). Although a retro-inverted BCL6 peptide inhibitor (RI-BPI) was recently...
3.
Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated
Navigante A, Castro M, Cerchietti L
J Pain Symptom Manage . 2010 May; 39(5):820-30. PMID: 20471543
Context: Cancer patients with dyspnea may be able to have the symptom pharmacologically controlled while its underlying cause is sought or treated. Objectives: This study was done to determine whether...
4.
A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo
Cerchietti L, Ghetu A, Zhu X, da Silva G, Zhong S, Matthews M, et al.
Cancer Cell . 2010 Apr; 17(4):400-11. PMID: 20385364
The BCL6 transcriptional repressor is the most frequently involved oncogene in diffuse large B cell lymphoma (DLBCL). We combined computer-aided drug design with functional assays to identify low-molecular-weight compounds that...
5.
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas
Cerchietti L, Lopes E, Yang S, Hatzi K, Bunting K, Tsikitas L, et al.
Nat Med . 2009 Dec; 15(12):1369-76. PMID: 19966776
We report that heat shock protein 90 (Hsp90) inhibitors selectively kill diffuse large B cell lymphomas (DLBCLs) that depend on the BCL-6 transcriptional repressor. We found that endogenous Hsp90 interacts...
6.
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
Cerchietti L, Yang S, Shaknovich R, Hatzi K, Polo J, Chadburn A, et al.
Blood . 2008 Oct; 113(15):3397-405. PMID: 18927431
The BCL6 transcriptional repressor is the most commonly involved oncogene in diffuse large B-cell lymphomas (DLBCLs). BCL6 lymphomagenic activity is dependent on its ability to recruit corepressor proteins to a...
7.
Sequential transcription factor targeting for diffuse large B-cell lymphomas
Cerchietti L, Polo J, da Silva G, Farinha P, Shaknovich R, Gascoyne R, et al.
Cancer Res . 2008 May; 68(9):3361-9. PMID: 18451163
Transcription factors play a central role in malignant transformation by activating or repressing waves of downstream target genes. Therapeutic targeting of transcription factors can reprogram cancer cells to lose their...